Project Grant R21CA293616
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $467K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Edison, NJ 08837, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with a completion date of April 30, 2031. This five-year research initiative will investigate the myeloid-stromal axis in colorectal cancer (CRC), specifically examining how interactions between macrophages and cancer-associated fibroblasts (CAFs) suppress anti-tumor immunity and promote tumor...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $660,541 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period April 1, 2026, through March 31, 2031. This award funds fundamental research investigating the modulation of the tumor microenvironment by Fusobacterium nucleatum (FN) and co-infecting microbes in colorectal cancer (CRC). The research addresses a critical gap in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $733,864 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. Using high-throughput CRISPR-based screening...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The project delivers scientific research services aimed at understanding how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $162,080 under the Cancer Research Manpower program (CFDA 93.398) on December 27, 2025, with a completion date of June 30, 2028. Dr. Komatsu's laboratory is conducting research to visualize and characterize B cell infiltration and aggregation within the tumor microenvironment, with particular focus on the role of high endothelial venules (HEVs) as critical gateways for...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate novel microbial-based therapeutic strategies targeting colibactin, a carcinogenic metabolite produced by enteric bacteria associated with colorectal cancer. The research will engineer nonpathogenic commensal microbes to deliver the CLBS resistance protein via bacterial surface...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Grant Award Summary The University of California, San Diego received a $671,226 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded May 15, 2026, with completion targeted for April 30, 2031. The project, "Colorectal Cancer Therapies Introduced Through Engineered Native Bacteria," will develop a microbial platform technology using engineered native E. coli strains derived from human gut bacteria to deliver...